Plain-English translation of NCT07828236 on ClinicalTrials.gov ↗ · Source last updated · Translation generated ·
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is one of the first times this treatment has been tested in people.
This is an early-stage trial testing a new immunotherapy called combined with low-dose gemcitabine in people with advanced pancreatic cancer that cannot be surgically removed. The medication is a genetically modified live bacteria designed to help your immune system recognize and fight cancer cells. Researchers will give the treatment directly into the abdomen (the space around your organs) to see if it is safe, what side effects occur, and what dose works best.
Advanced pancreatic cancer is very difficult to treat, and patients who have already tried standard treatments have few options left. This trial exists because researchers believe that this new immunotherapy approach might help people whose cancer has not responded to or progressed after earlier treatments.
You likely qualify if…
You likely don't qualify if…
During screening, you will have blood tests to check your immune response to tetanus and receive a tetanus booster vaccine if needed. Before treatment starts, a small surgically placed port (like a tiny tube) will be put in your abdomen to deliver the medication. You will then receive escalating doses of the new medication injected into your abdomen along with low-dose chemotherapy. The trial involves about 18 participants total, and researchers will carefully monitor your health with regular visits, blood tests, and scans to track how well the treatment works and what side effects occur.
AI-generated summary from trial data · Nov 17, 2026 · Not medical advice
United States